Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Biocraft Labs sales jumped 49.2% to $ 28.2 mil. in the second quarter of fiscal 1990 and 44.7% to $ 52.2 mil. for the first half (ended Sept. 30), the company reported Nov. 9. "As expected, sales and earnings benefited significantly from initial sales" of amiloride/hydrochlorothiazide "as well as [from] continued sales of cefadroxil," President Harold Snyder said. Net earnings for the quarter were $ 4.7 mil., more than 200% higher than in the comparable quarter of fiscal 1989. Income for six months was also more than 200% greater, at $ 8.3 mil. Biocraft launched its generic version of Merck's Moduretic potassium-conserving agent/diuretic combination in July. The company received six months of exclusivity in May when an appellate court ruled that Merck's patent on the drug was invalid ("The Pink Sheet" May 15, T&G-9). The firm began selling generic cefadroxil in mid-March along with Purepac following two favorable court rulings against patent holder Bristol-Myers ("The Pink Sheet" March 13, p. 15). * Elan reported a 104% leap in second quarter revenues to $ 11.6 mil. (IR(BRITISH POUND)8.2 mil.), while net profits grew 60% to $ 967,000 (IR(BRITISH POUND)679,000). For the six months ended Sept. 30, revenues grew 144% to $ 23.6 mil. (IR(BRITISH POUND)16.6 mil.), generating a net profit of $ 1.9 mil. (IR(BRITISH POUND)1.3 mil.). Elan attributed its performance to "the introduction and marketing in the U.S. of Cardizem SR by Marion Labs, increased licensing income, and a substantial increase in revenues from the inclusion of O'Brien/KMI," which was acquired last March 17. Elan said it anticipates that O'Brien/KMI "will be making profits by the end of this fiscal year." Chart omitted.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts